Demographic and clinical characteristics of spondyloarthritis patients in Jordan: A cross-sectional study
- PMID: 40377764
- DOI: 10.1007/s10067-025-07487-9
Demographic and clinical characteristics of spondyloarthritis patients in Jordan: A cross-sectional study
Abstract
Background/aim: Spondyloarthritis (SpA) is a group of chronic inflammatory rheumatic diseases with various subtypes. Given the limited research on SpA demographics and characteristics in the region, this study aims to provide insight into SpA in Jordan.
Methods: A cross-sectional study of patients diagnosed with SpA according to the Assessment of SpondyloArthritis International Society (ASAS) criteria who attended rheumatology clinics at two tertiary care centers between January and September 2023. Data on clinical, laboratory, and imaging findings were collected, and the prevalence of fibromyalgia was assessed using the FiRST tool.
Results: Among 155 patients, 51% were male, with a mean age of 43.8 ± 12.7 years and a disease duration of 8.12 ± 8.7 years. The diagnostic delay averaged 4.49 ± 5.6 years. Ankylosing spondylitis was diagnosed in 43.2%, non-radiographic axial SpA in 7.7%, and psoriatic arthritis in 58%. Six patients (3.9%) had undergone hip replacement. Fibromyalgia was present in 25.3%, significantly linked to enthesitis (P < 0.001). Biological DMARDs (B-DMARDs) were used by 68.4% of patients, and conventional synthetic DMARDs (Cs-DMARDs) by 46.5%. Males were more likely to have elevated CRP levels (P = 0.041), while females had a higher prevalence of enthesitis (P = 0.013) and were more likely to use CS-DMARDs (P = 0.001).
Conclusion: SpA was associated with gender differences, with males having higher CRP levels and females experiencing more enthesitis and greater Cs-DMARD use. Diagnostic delay remains an issue and may have contributed to disease progression, leading to hip replacement in some patients. Further research is necessary to elucidate these distinctions more precisely.
Keywords: Ankylosing spondylitis; Cross sectional study; Epidemiology; Psoriatic arthritis; Spondylarthritis.
© 2025. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).
Conflict of interest statement
Declarations. Ethics approval and consent to participate: The study protocol was approved by the institutional review board at the Jordan University Hospital (protocol number 10/2023/9355). All patients were informed and consented, and they were assured of data protection and confidentiality. The study was conducted in accordance with the principles outlined in the Declaration of Helsinki. Consent for publication: Not applicable. Clinical trial number: Not applicable. Competing interests: The authors declare no competing interests. Disclosure of AI use:: Grammarly ( https://app.grammarly.com/ )was utilized to enhance the grammar and clarity of this manuscript.
Similar articles
-
Combination therapy for pain management in inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis).Cochrane Database Syst Rev. 2011 Oct 5;(10):CD008886. doi: 10.1002/14651858.CD008886.pub2. Cochrane Database Syst Rev. 2011. PMID: 21975788
-
Safety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis).Cochrane Database Syst Rev. 2011 Nov 9;(11):CD008872. doi: 10.1002/14651858.CD008872.pub2. Cochrane Database Syst Rev. 2011. PMID: 22071858
-
Sulfasalazine for ankylosing spondylitis.Cochrane Database Syst Rev. 2005 Apr 18;(2):CD004800. doi: 10.1002/14651858.CD004800.pub2. Cochrane Database Syst Rev. 2005. Update in: Cochrane Database Syst Rev. 2014 Nov 27;(11):CD004800. doi: 10.1002/14651858.CD004800.pub3. PMID: 15846731 Updated.
-
Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. doi: 10.3310/hta10310. Health Technol Assess. 2006. PMID: 16948890
-
A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.Health Technol Assess. 2006 Nov;10(42):iii-iv, xi-xiii, 1-229. doi: 10.3310/hta10420. Health Technol Assess. 2006. PMID: 17049139
References
-
- Dougados M, Baeten D (2011) Spondyloarthritis Lancet 377:2127–2137. https://doi.org/10.1016/S0140-6736(11)60071-8 - DOI
-
- Taitt HA, Balakrishnan R (2023) Spondyloarthritides. Immunol Allergy Clin North Am 43:593–612. https://doi.org/10.1016/j.iac.2022.10.001 - DOI
-
- Walsh JA, Magrey M (2021) Clinical Manifestations and Diagnosis of Axial Spondyloarthritis. J Clin Rheumatol 27:e547–e560. https://doi.org/10.1097/RHU.0000000000001575 - DOI
-
- Lories RJ (2018) Advances in understanding the pathophysiology of spondyloarthritis. Best Pract Res Clin Rheumatol 32:331–341. https://doi.org/10.1016/j.berh.2018.12.001 - DOI
-
- Role of HLA-B27 in the pathogenesis of ankylosing spondylitis (Review) - PubMed. https://pubmed.ncbi.nlm.nih.gov/28259985/ . Accessed 11 Jan 2025
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous